Attached files
file | filename |
---|---|
EX-99.1 - Protagenic Therapeutics, Inc.\new | v166197_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of
Report (Date of Earliest Event Reported): November 11, 2009
ATRINSIC,
INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
001-12555
|
06-1390025
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
469
7th
Avenue, 10th Floor,
New York, NY 10018
(Address
of Principal Executive Offices/Zip Code)
(212)
716-1977
(Registrant’s
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions ( see
General Instruction A.2. below):
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
2.02.
|
Results of Operations and
Financial Condition
|
On
November 11, 2009, Atrinsic, Inc. held a conference call regarding its financial
results for the three and nine month periods ending September 30, 2009, a copy
of the transcript of the conference call is attached hereto as Exhibit
99.1.
The
information in this Current Report on Form 8-K, including the exhibit, is
furnished pursuant to Item 2.02 and shall not be deemed “filed” for the purposes
of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933, except
as shall be expressly set forth by specific reference in such
filing.
In
addition to historic information, this report, including the exhibit, contains
forward-looking statements regarding events, performance and financial trends.
Various factors could affect future results and could cause actual results to
differ materially from those expressed in or implied by the forward-looking
statements. Some of those factors are identified in the exhibit, and in our
periodic reports filed with the Securities and Exchange Commission.
Item
9.01.
|
Financial
Statements and Exhibits
|
(d)
|
Exhibits.
The
following exhibit is filed
herewith:
|
Exhibit
Number
|
Description
|
|
99.1
|
Transcript
of conference call held on November 11,
2009
|
2
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Atrinsic,
Inc.
|
|||
Date:
November 16, 2009
|
By:
|
/s/
Andrew Zaref
|
|
Andrew
Zaref
|
|||
Chief
Financial Officer
|
|||
3
4